Your browser doesn't support javascript.
loading
Characterizing the Cellular Immune Response to Parainfluenza Virus 3.
Aguayo-Hiraldo, Paibel I; Arasaratnam, Reuben J; Tzannou, Ifigeneia; Kuvalekar, Manik; Lulla, Premal; Naik, Swati; Martinez, Caridad A; Piedra, Pedro A; Vera, Juan F; Leen, Ann M.
Afiliação
  • Aguayo-Hiraldo PI; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital.
  • Arasaratnam RJ; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital.
  • Tzannou I; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital.
  • Kuvalekar M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital.
  • Lulla P; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital.
  • Naik S; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital.
  • Martinez CA; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital.
  • Piedra PA; Baylor College of Medicine, Houston, Texas.
  • Vera JF; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital.
  • Leen AM; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital.
J Infect Dis ; 216(2): 153-161, 2017 07 15.
Article em En | MEDLINE | ID: mdl-28472480
ABSTRACT
Parainfluenza virus type 3 (PIV3) infections are a major cause of morbidity and mortality in immunocompromised individuals, with no approved therapies. Our group has demonstrated the safety and efficacy of adoptively transferred virus-specific T cells for the prevention and treatment of a broad range of viral infections including BK virus, cytomegalovirus, adenovirus, human herpesvirus 6, and Epstein-Barr virus. However, this approach is restricted to well-characterized viruses with known immunogenic/protective T-cell target antigens, precluding extension to PIV3. We now characterize the cellular immune response to all 7 PIV3-encoded antigens in 17 healthy donors and define a hierarchy of immunogenicity based on the frequency of responding donors and the magnitude of specific cells. We show that reactive populations of both CD4+ and CD8+ T cells are capable of producing Th1-polarized effector cytokines and killing PIV3-expressing targets. Furthermore, we confirm the clinical relevance of these cells by demonstrating a direct correlation between the presence of PIV3-specific T cells and viral control in allogeneic hematopoietic stem cell transplant recipients. Taken together, our findings support the clinical use of PIV3-specific T cells produced with our Good Manufacturing Practice-compliant manufacturing process, in immunocompromised patients with uncontrolled infections.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por Respirovirus / Leucócitos Mononucleares / Linfócitos T / Vírus da Parainfluenza 3 Humana / Imunidade Celular / Antígenos Virais Limite: Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por Respirovirus / Leucócitos Mononucleares / Linfócitos T / Vírus da Parainfluenza 3 Humana / Imunidade Celular / Antígenos Virais Limite: Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article